Milton Werner
Founder chez INHIBIKASE THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Milton H.
Werner is the founder of Inhibikase Therapeutics, Inc. which was founded in 2008.
He holds the title of President, Chief Executive Officer & Director at Inhibikase Therapeutics, Inc. starting in 2012.
Dr. Werner is currently a Member at Winship Cancer Institute.
In the past, he worked as Vice President-Research at Celtaxsys, Inc. in 2007 and as Head-Laboratory of Molecular Biophysics at The Rockefeller University from 1996 to 2007.
Dr. Werner completed his undergraduate degree at the University of Southern California in 1985 and obtained his doctorate degree from the University of California, Berkeley in 1991.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 889 230 ( 14,37% ) | 2 M $ | 31/03/2024 |
Postes actifs de Milton Werner
| Sociétés | Poste | Début |
|---|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Founder | 01/09/2008 |
| Winship Cancer Institute | Corporate Officer/Principal | - |
Anciens postes connus de Milton Werner
| Sociétés | Poste | Fin |
|---|---|---|
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Chief Tech/Sci/R&D Officer | 01/08/2007 |
| The Rockefeller University | Corporate Officer/Principal | 01/06/2007 |
Formation de Milton Werner
| University of Southern California | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INHIBIKASE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
| Winship Cancer Institute |
